Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects

Huda, M. S. B., Durham, B. H., Wong, S. P., Dovey, T. M., McCulloch, P., Kerrigan, D., Pinkney, J. H., Fraser, W. D. and Wilding, J. P. H. (2007) Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. Bone, 41 (3). pp. 406-413. ISSN 1873-2763

Full text not available from this repository. (Request a copy)

Abstract

Background: Ghrelin is a gut-brain peptide that powerfully stimulates appetite and growth hormone secretion and is also known to directly regulate osteoblast cell function in vitro and in animal models. Little is known about the effects of ghrelin on bone turnover in humans. As the stomach is the main site of ghrelin synthesis, gastrectomy patients are deficient in ghrelin; they are also prone to osteopenia and osteomalacia.   Hypothesis: Ghrelin may play a role in bone regulation in humans; ghrelin deficiency following gastrectomy is associated with the disrupted regulation of bone turnover seen in these subjects. Subjects and methods: In a randomised, double-blind, placebo-controlled study 8 healthy controls and 8 post-gastrectomy subjects were infused with intravenous ghrelin (5 pmol/kg/min) or saline over 240 min on different days. Subjects were given a fixed energy meal during the infusion. Ghrelin, GH, type-1 collagen β C-telopeptide (βCTX), a marker of bone resorption, and procollagen type-1 amino-terminal propeptide (P1NP), a marker of bone formation, were measured. Results: Fasting ghrelin was significantly lower in the gastrectomy group during the saline infusion (226.1 ± 62.0 vs. 762 ± 71.1 ng/l p < 0.001). Growth hormone was significantly higher at 90 min after the ghrelin infusion, compared to saline in both healthy controls (61.1 ± 8.8 vs. 1.4 ± 0.6 mIU/l p < 0.001) and gastrectomy subjects (61.1 ± 11.8 vs. 0.9 ± 0.2 mIU/l p < 0.001) confirming the ghrelin was bioactive. Gastrectomy subjects were significantly older and had significantly higher plasma βCTX than healthy controls at all time points (ANOVA p = 0.009). After adjustment for age and BMI ghrelin was found to be a significant predictor of baseline plasma βCTX and was inversely correlated with baseline plasma βCTX (β = − 0.54 p = 0.03 R2 = 26%). However, there was no significant effect of the ghrelin infusion on plasma βCTX or P1NP in either subject group. Conclusions: Ghrelin infusion has no acute effect on markers of bone turnover in healthy controls and post-gastrectomy subjects, but is inversely correlated with bone resorption.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	Rhiannon Harvey
Date Deposited:	08 Jun 2011 13:36
Last Modified:	24 Sep 2024 09:37
URI:	https://ueaeprints.uea.ac.uk/id/eprint/32071
DOI:	10.1016/j.bone.2007.05.006

Actions (login required)

View Item